Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Though there are multiple possible reasons that people may discontinue treatment with GLP-1 receptor agonists, high ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death ... based Mayo Clinic researchers analyzed the effect GLP-1s and SGLT2s medications had on stroke survivors' risk of ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

GLP-1 receptor agonists, originally developed for managing type ... gained widespread attention for its significant weight ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...